SK41593A3 - Using of inhibitors of plasminogene activators for the production of medicament for a therapy of ignitions and wounds - Google Patents

Using of inhibitors of plasminogene activators for the production of medicament for a therapy of ignitions and wounds Download PDF

Info

Publication number
SK41593A3
SK41593A3 SK415-93A SK41593A SK41593A3 SK 41593 A3 SK41593 A3 SK 41593A3 SK 41593 A SK41593 A SK 41593A SK 41593 A3 SK41593 A3 SK 41593A3
Authority
SK
Slovakia
Prior art keywords
treatment
plasminogen activator
corneal
activator inhibitors
pai
Prior art date
Application number
SK415-93A
Other languages
English (en)
Slovak (sk)
Inventor
Eckhard Schuler
Jurgen Romisch
Eric-Paul Paques
Gerhard Dickneite
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of SK41593A3 publication Critical patent/SK41593A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK415-93A 1992-04-30 1993-04-28 Using of inhibitors of plasminogene activators for the production of medicament for a therapy of ignitions and wounds SK41593A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4214215A DE4214215A1 (de) 1992-04-30 1992-04-30 Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen

Publications (1)

Publication Number Publication Date
SK41593A3 true SK41593A3 (en) 1993-11-10

Family

ID=6457814

Family Applications (1)

Application Number Title Priority Date Filing Date
SK415-93A SK41593A3 (en) 1992-04-30 1993-04-28 Using of inhibitors of plasminogene activators for the production of medicament for a therapy of ignitions and wounds

Country Status (16)

Country Link
EP (1) EP0567816A1 (cs)
JP (1) JPH069425A (cs)
KR (1) KR930021179A (cs)
CN (1) CN1080873A (cs)
AU (1) AU3822993A (cs)
CA (1) CA2095207A1 (cs)
CZ (1) CZ76893A3 (cs)
DE (1) DE4214215A1 (cs)
HU (1) HUT65755A (cs)
IL (1) IL105521A0 (cs)
MX (1) MX9302519A (cs)
NO (1) NO931561L (cs)
PL (1) PL298748A1 (cs)
SK (1) SK41593A3 (cs)
UY (1) UY23572A1 (cs)
ZA (1) ZA933023B (cs)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
GB2271507A (en) * 1992-09-04 1994-04-20 Summit Technology Ireland Bv Compositions containing plasmin activity inhibitors
CA2472404A1 (en) 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combination of stent and anti-angiogenic factor
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6344189B1 (en) * 1998-04-01 2002-02-05 Biotech Australia Pty., Ltd. Use of protease inhibitors for treating skin wounds
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
WO2000066139A2 (en) 1999-04-29 2000-11-09 Ista Pharmaceuticals, Inc. Biochemical methods that eliminate corneal scars, opacification and haze
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
JP3690720B2 (ja) 1999-09-14 2005-08-31 インターナショナル・ビジネス・マシーンズ・コーポレーション クライアントサーバーシステム、オブジェクトのプール方法および記憶媒体
DE60020727T2 (de) 1999-10-27 2006-05-04 Robert London Zhong Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
JP2001247458A (ja) * 2000-03-08 2001-09-11 Hamari Chemicals Ltd トラネキサム酸亜鉛化合物を含む糖尿病治療剤
AU2001291579B2 (en) 2000-09-29 2006-08-31 Viron Therapeutics Inc. Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
DE60133053T2 (de) 2000-10-16 2009-02-26 Conor Medsystems, Inc., Menlo Park Ausdehnbare medizinische Vorrichtung zur Abgabe eines nützlichen Agens
US6964680B2 (en) 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
AT500019B1 (de) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm Verwendung in vitro des transkriptionsfaktors nak-1 oder von nak-1 regulierten genen zur diagnose von entzündlichen und malignen erkrankungen
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
US7169179B2 (en) 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
CN101977626A (zh) * 2008-01-21 2011-02-16 德莫迪斯公司 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
TWI763960B (zh) * 2017-12-15 2022-05-11 大陸商深圳瑞健生命科學研究院有限公司 一種預防或治療骨關節炎的方法及藥物
CN119044501A (zh) * 2024-07-17 2024-11-29 浙江大学 一种pai-2泪液浓度检测试剂在制备大气细颗粒物致眼表损伤或疾病鉴别试剂盒中的应用
CN118557734B (zh) * 2024-07-24 2024-11-22 中山大学中山眼科中心 Serpinb2抑制剂在制备用于治疗湿性年龄相关性黄斑变性药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829523A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression
DE69031271T2 (de) * 1989-12-20 1998-02-26 Biotech Australia Pty Ltd Varianten von pai-2
EP0451130A3 (en) * 1990-04-05 1992-08-05 Baltimore Biotech, Inc. Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization

Also Published As

Publication number Publication date
PL298748A1 (en) 1993-12-27
IL105521A0 (en) 1993-08-18
HU9301272D0 (en) 1993-07-28
CZ76893A3 (en) 1994-01-19
HUT65755A (en) 1994-07-28
CN1080873A (zh) 1994-01-19
CA2095207A1 (en) 1993-10-31
AU3822993A (en) 1993-11-04
JPH069425A (ja) 1994-01-18
MX9302519A (es) 1993-10-01
ZA933023B (en) 1994-10-31
KR930021179A (ko) 1993-11-22
NO931561D0 (no) 1993-04-29
UY23572A1 (es) 1993-05-04
EP0567816A1 (de) 1993-11-03
DE4214215A1 (de) 1993-11-04
NO931561L (no) 1993-11-01

Similar Documents

Publication Publication Date Title
SK41593A3 (en) Using of inhibitors of plasminogene activators for the production of medicament for a therapy of ignitions and wounds
EP1904108B1 (en) Ophthalmological formulation comprising methylsulfonylmethane and ciprofloxacin
AU2003297511B2 (en) Ophthalmic formulation for the prevention and treatment of ocular conditions
US7348306B2 (en) Composition for promoting lacrimal secretion
US20060172972A1 (en) Formulation and method for administration of ophthalmologically active agents
KR20060109947A (ko) 황반 변성 및 다른 안과 질환의 개선
WO2007011875A2 (en) Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US6610686B1 (en) Use of pirenoxine for the protection of corneal tissues in photokeractomy
Almond et al. 5-fluorouracil and mitomycin-C: adjuncts to pterygium surgery
KR20010040457A (ko) 안약 조성물
KR20010041337A (ko) 각막 상피 장애증 치료제
Kondo et al. Iontophoresis of 5-fluorouracil into the conjunctiva and sclera.
CA2515022A1 (en) Method for treating elevated intraocular pressure, including glaucoma
RU2284181C2 (ru) Фармацевтическая композиция для профилактики инфекции в офтальмологии "интрависк"
US8283323B2 (en) Withanolide compounds as inhibitors of fibrosis and identification of molecular targets for anti-fibrotic drug development
JP3579063B2 (ja) 緑内障の治療に有用な薬剤の製造のためのｘ−ａｒｇ−ｇｌｙ−ａｓｐ−ｙの使用法
Gayre Medical management of thyroid eye disease
JPWO1999043347A1 (ja) 角膜上皮障害症治療剤
CZ20002770A3 (cs) Oční prostředky